Stocks and Investing Stocks and Investing
Mon, January 30, 2023
Sun, January 29, 2023
Fri, January 27, 2023

Michael Ulz Maintained (BPMC) at Hold with Decreased Target to $50 on, Jan 27th, 2023


Published on 2024-10-28 01:11:05 - WOPRAI, Michael Ulz
  Print publication without navigation


Michael Ulz of Morgan Stanley, Maintained "Blueprint Medicines Corporation" (BPMC) at Hold with Decreased Target from $75 to $50 on, Jan 27th, 2023.

Michael has made no other calls on BPMC in the last 4 months.



There are 10 other peers that have a rating on BPMC. Out of the 10 peers that are also analyzing BPMC, 4 agree with Michael's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Peter Lawson of "Barclays" Maintained at Hold with Decreased Target to $44 on, Monday, January 23rd, 2023
  • Derek Archila of "Wells Fargo" Upgraded from Sell to Hold and Held Target at $41 on, Tuesday, January 3rd, 2023
  • Andrew Berens of "SVB Leerink" Maintained at Hold with Decreased Target to $52 on, Wednesday, November 2nd, 2022
  • Matthew Biegler of "Oppenheimer" Downgraded from Buy to Hold on, Wednesday, November 2nd, 2022


These are the ratings of the 6 analyists that currently disagree with Michael


  • Ami Fadia of "Needham" Initiated at Strong Buy and Held Target at $60 on, Wednesday, December 14th, 2022
  • Reni Benjamin of "JMP Securities" Maintained at Buy with Decreased Target to $114 on, Friday, November 4th, 2022
  • Terence Flynn of "Goldman Sachs" Maintained at Strong Buy with Decreased Target to $108 on, Thursday, November 3rd, 2022
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $70 on, Wednesday, November 2nd, 2022
  • Liana Moussatos of "Wedbush" Maintained at Buy with Decreased Target to $106 on, Wednesday, November 2nd, 2022
  • Michael Schmitz of "Guggenheim" Maintained at Strong Buy with Decreased Target to $85 on, Wednesday, November 2nd, 2022
Contributing Sources